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Abstract
One of the roadblocks to developing effective therapeutics for Huntington disease (HD) is
the lack of animal models that develop progressive clinical traits comparable to those seen
in patients. Here we report a longitudinal study that encompasses cognitive and motor as-
sessment, and neuroimaging of a group of transgenic HD and control monkeys from infancy
to adulthood. Along with progressive cognitive and motor impairment, neuroimaging re-
vealed a progressive reduction in striatal volume. Magnetic resonance spectroscopy at 48
months of age revealed a decrease of N-acetylaspartate (NAA), further suggesting neuro-
nal damage/loss in the striatum. Postmortem neuropathological analyses revealed signifi-
cant neuronal loss in the striatum. Our results indicate that HD monkeys share similar
disease patterns with HD patients, making them potentially suitable as a preclinical HD
animal model.
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Introduction
Huntington disease (HD) is a devastating autosomal dominant neurodegenerative disease
caused by the expansion of polyglutamine (polyQ) residues (>36Q) in exon 1 of the huntingtin
(HTT or IT15) gene. A major challenge in the study of HD pathogenesis and the development
of effective therapies is that the currently available animal models cannot replicate the full spec-
trum of HD clinical and pathological features, among them motor symptoms, cognitive behav-
ioral deficits, and neuropathological changes of the striatum [1,2,3,4]. Establishing a transgenic
monkey model for HD (HDmonkeys) could allow us to evaluate the long-term disease process
via clinical assessments comparable to those used in human patients and to monitor the effects
of novel therapeutics throughout treatment [3,4,5].
There have been many advances in our understanding of HD etiology and pathogenesis.
Current research initiatives involve deciphering the mechanisms behind disease onset and im-
proving animal models to aid in the search for a cure. Amongst the key clinical signs of HD are
a progressive impairment in motor function and abnormal involuntary movements, such as
chorea and dystonia. Recent longitudinal neuroimaging studies of HD patients suggested that
non-invasive MRI provides an optimal quantitative tool for determining anatomical changes
that are highly correlated with the development and progression of cognitive behavioral and
motor impairments throughout the course of HD [6,7,8,9].
We established a group of transgenic HD rhesus monkeys (n = 4; rHD1, rHD6, rHD7, and
rHD8; males) and compared them with a group of age-matched non-transgenic control rhesus
monkeys (WT monkeys; n = 4; 2 males and 2 females). These animals were enrolled in a longi-
tudinal study that encompassed cognitive and motor assessment combined with in vivo neuro-
imaging and postmortem pathological analyses. The huntingtin (HTT) gene of rhesus
macaques normally carries 10–11 polyQ repeats [10], while humans normally carry 9–35 re-
peats [11,12,13]. In our study, rHD1 carried exon 1 of the humanHTT gene regulated by
human polyubiquitin-C promoter, which expressed N-terminal 67 amino acids with 29 polyQ
repeats [4]. rHD6, 7, and 8 (rHDs6-8), on the other hand, carried exons 1–10 of the human
HTT gene coding N-terminal 508 amino acids with approximately 67-72Q under the control
of the human HTT promoter. rHD1 developed facial chorea and dystonia at around 18 months
of age and had his first episode of seizures at 24 months of age. On the other hand, we saw no
chorea in rHDs6-8, and dystonia was first observed at 24 months of age (S1 Fig). Because of
the distinct genotypes of rHD1 versus rHDs-6-8, a more aggressive form of HD reminiscent of
juvenile HD was expected in rHD1 because he expressed a smaller N-terminal mHTT under
the ubiquitin promoter [3]. On the other hand, rHDs6-8 were expected to express the mutant
HTT transgene similarly to the endogenous HTT gene. As a result of the regulation by human
HTT promoter and a larger HTT fragment, we anticipated a slower HD progression similar to
adult-form HD in rHDs6-8. Our longitudinal characterization of clinically manifested symp-
toms and neuroanatomical changes in HD monkeys could give us valuable information about
the onset and/or progression of HD symptoms and pathology in these animals. The develop-
ment and evaluation of such a potential preclinical nonhuman primate HD model could be
pivotal for the development of novel therapeutics and clinical interventions for the treatment
of HD in humans.
Materials and Methods
Ethics statement
All animal procedures (e.g., housing, testing) were performed in a BSL-2 facility at the Yerkes
National Primate Research Center (YNPRC) and were approved by the Emory University
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Institutional Animal Care and Use Committee (IACUC). Animal research was conducted in
compliance with the Animal Welfare Act and other Federal statutes and regulations relating to
animals and experiments involving animals and adheres to the principles stated in the Guide
for the Care and Use of Laboratory Animals prepared by the National Research Council. Yerkes
National Primate Research Center is a fully AAALAC-accredited facility. All animals in the
colony are managed in accordance with the applicable USDA Animal Welfare Regulations and
the Guide for the Care and Use of Laboratory Animals. All procedures were approved by the
Emory Health and Biosafety Committee (EHSO). Transgenic HDmonkeys were created by
lentiviral transfection of rhesus mature oocytes, followed by in vitro fertilization, culture, and
embryo transfer into surrogate female macaques as previously described [4]. Cognitive motor
assessment was performed and monitored by the research staff and veterinary staff during ex-
perimental procedures and on a routine basis following established procedures. All MR imag-
ing experiments were performed using a 3T scanner.
Production of transgenic Huntington disease monkeys (HD monkeys)
Four male transgenic HD rhesus macaques (“rHD1” and “rHD6, rHD7, rHD8”) were created
by transfection of mature oocytes by using a lentiviral vector carrying a mutant form of the
HTT gene [4]. For rHD1, the insert contained exon 1 of the humanHTT gene bearing expand-
ed polyglutamine (PolyQ) repeats (29Q and 83Q, respectively) under the control of a human
polyubiquitin C promoter, as described previously [4]. For the remaining 3 transgenic HD
monkeys, rHDs6-8, the lentiviral vector contained the first 11 exons of the humanHTT gene
bearing the first 508 amino acids and an expanded polyQ (67Q, 70Q, and 72Q, respectively)
under regulation by the human HTT promoter [5]. All HD monkeys, as well as 4 age-matched
wild-type non-transgenic (WT) control monkeys (2 males and 2 females), were raised in the
same primate nursery. They all received the same treatments and procedures designed for the
longitudinal study, including cognitive motor assessment and MRI scans. All animals were
monitored at least twice daily from birth by the research team or by animal care personnel at
the YNPRC. In addition to euthanasia guidelines of the YNPRC, we have developed specific eu-
thanasia guidelines based on functional assessment of HD monkeys; we assess feeding behav-
ior, monitor weight, urination, and defecation, and daily activity, as well, as if the animals are
alert and responsive. Besides daily functional assessment, the occurrence of adverse events,
such as the development of self-injurious behavior (SIB), prompts us to seek an immediate vet-
erinarian consultation for appropriate resolution and medications. Euthanasia is considered if
medical justification is reached. In the case of rHD1, SIB developed initially due to stress, such
as during the cognitive behavioral test (e.g., Life Saver Task). Our first step to minimize the suf-
fering of the animal from abnormal behavioral conditions was to stop all tests to eliminate the
potential stress. Due to the progression of the disease and continued development of SIB, medi-
cations, including analgesics, anticonvulsants, and antidepressants, were provided to relieve
the suffering of rHD1. However, euthanasia had to be considered based on concerns for the
well-being and medical condition of the animal.
Post-delivery, infants were surrogate-nursery reared in the primate nursery of the YNPRC
according to procedures developed by Sackett and colleagues [38] that allow normal growth as
well as the development of species-specific social skills. These procedures included daily social
interactions with peers, intensive human contact, and cognitive testing that began in the first
weeks of life and continued through adulthood [39].
Diet consisted of infant Similac formula (SMA with iron) supplemented with banana pellets
starting at 3–4 weeks old (190 mg, P.J. Noyes, Cleveland, OH). Starting around 8 months of
age, they were fed jumbo primate chow (Lab Diet #5037, PMI Nutrition International Inc.,
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Brentwood, MO) and fresh fruit daily. All experimental procedures were approved by the Insti-
tutional Animal Care and Use Committee of Emory University (Atlanta, GA) and conformed
to the NIH Guide for the Care and Use of Laboratory Animals.
Behavioral testing
HD andWT monkeys were tested at different points throughout development to follow their
neurobehavioral and motor development. Animals were transferred to a Wisconsin General
Testing Apparatus (WGTA), facing a test tray onto which objects or equipment could be posi-
tioned. Rewards were given according to each animal’s preference, and included either peanuts,
raisins, fruity gems, mini M&M’s, marshmallows, or a ring-shaped candy (“Life Saver”) for the
VS-OR task (see below).
For the Object Retrieval Detour Task (ORDT; Detour/Barrier), the apparatus consisted of a
small transparent box (5” x 5” x 4”) opened on only one side and fixed on a tray. The box could
be located at different positions on the tray and could be rotated so that its open side could be
changed. The positions of the reward within the box (at the entrance but out of the box, one-
third in, half-way in, and three-quarters in), the box on the tray (left, right, center), and the ori-
entation of the open side of the box relative to the subject (front, left, right) were parametrically
varied. Subjects were allowed unlimited time to retrieve the reward as long as they continued
attempting to respond. A maximum of 3 minutes during which no responses occurred termi-
nated the trial and was scored as a “failure.” Training consisted of 7 testing days as follows. Day
1: Fifteen trials were given with the opening of the box facing towards the animal, such that all
trials involved a direct reach for the reward not requiring the animal to inhibit reaching at the
barrier. Days 2–4: Test sessions consisted of 18 trials, in which the trials required the animal to
either make a direct reach (box opening facing the animal) or to negotiate a detour
(box opening facing right or left of the animal). These 2 trial types were intermixed within a
session. Days 5–7: The plastic box was positioned at the center of the box for all trials. Daily
test sessions consisted of 21 trials requiring the animal to negotiate a detour on one side 5
times in the row, followed by a switch requiring the animal to negotiate a detour in the other
side 5 times in a row and so on (e.g., box opening on the left, left, left, left, left, then
box opening on the right, right, right, right, right, etc.). These trials were included to increase
the tendency for animals to exhibit perseverative responses, defined as successive repetitions of
a previously rewarded reach. All testing was video recorded, and the video tapes were subse-
quently analyzed by an experimenter blind to animal treatment (HD or WT). Several measures
of performance were included and are listed in S1 Table. Animals were tested on this task at 2
developmental time points (8 and 16 months).
In the visuospatial orientation (VS-OR) task, the monkeys had to free a ring-shaped candy
(“Life Saver”) by moving it along a metal rod that was bent into simple to complex detour pat-
terns or routes. A testing tray with a vise at its center onto which metal-rods were secured was
used. Metal rods were either straight for the pre-training phase or had 1–3 bends for the “easy
routes” and 4–5 bends for the “difficult routes” (see Fig 1 in Bachevalier et al., 1991 for details
of the metal rods used) [22]. On each trial the central pole of a metal-rod route was inserted
into the vise, and a Life Saver was threaded along the rod back to the starting point, located on
either the right or the left side of the central pole. Monkeys were required to retrieve the Life
Saver by threading it to the free end of the rod. The test was composed of 3 stages. Pre-training
stage: the animal learned to remove the Life Saver from a straight rod placed in 1 of 4 different
orientations (up, right, left, and toward the monkey) during 12 daily sessions. The monkey was
given 6 practice trials for each orientation in which the experimenter helped the animal free
the Life Saver if necessary. Six test trials at each orientation on each of 3 days were performed
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after the practice trials. The monkey performed these test trials without experimenter help, and
the time to retrieve the Life Saver was recorded. Second stage: pseudorandomly 3 times each
for a total of 36 trials were presented as 12 “easy” routes. Each animal received 6 of these trials
per day for 6 consecutive days, and a maximum of 45 seconds was allowed to retrieve the Life
Saver. For the third and final stage, 12 “difficult” routes were presented similar to the second
stage, and a maximum of 120 seconds were allowed to retrieve the reward. This task was given
at both 16 and 36 months, except for rHD1, who was tested at the first time point only (i.e. 16
months). The VS-OR task or the “Life Saver” task procedure was previously described in detail
by Bachevalier and colleagues in 1991 [22].
Statistical comparisons for all behavioral data were carried out using the SYSTAT 13 soft-
ware. Comparisons between controls and HD animals were performed using 2-way ANOVA
with repeated measures when the assessments were done longitudinally across ages, followed
by post-hoc analyses. One-sided, 2-sample t-tests were used to conduct between-group com-
parisons. When data were not distributed normally, Mann-Whitney U tests were used for
group comparisons.
MR image and spectroscopy data acquisition
All MRI experiments were performed using a Siemens 3T Trio scanner (Siemens Medical Solu-
tions, Inc, Malvern, PA, USA) with a CP extremity volume coil (for 6-, 12-, 18-, and 24-month
scans) and an 8-channel phased-array knee coil (Invivo Inc, FL, USA) (for 30-, 36-, 42-, and
48-month scans). Animals were immobilized in the supine position with the head secured in a
custom-made head holder. Anesthesia was maintained with 1–1.5% isoflurane mixed with O2.
Et-CO2, inhaled CO2, O2 saturation, blood pressure, heart rate, respiration rate, and body tem-
perature were monitored continuously and maintained in normal ranges [40]. T1-weighted im-
ages were acquired using a 3D magnetization-prepared rapid acquisition gradient echo
(MPRAGE) sequence with the parameters: TR = 2500 ms, TE = 3.48 ms, TI = 950 ms, FOV = 96
mm x 96 mm, data matrix = 192 X 192, flip angle = 8 degree, slice thickness = 0.5 mm, 208 slices,
and 6 averages. Single-voxel proton magnetic resonance spectroscopy (1H-MRS) was performed
using a PRESS (Point Resolved Spectroscopy) sequence combined with the CHESS water
Fig 1. Object retrieval detour task (ORDT) at 8 and 16 months of age.ORDT was performed at 8 (a-d; top
panel) and 16 (e-h; bottom panel) months of age. Scores are (a, e) latency (sec) to retrieve the reward, (b, f)
frequency of reaching through the transparent plastic barrier, (c, g) number of motor problems, and (d, h)
frequency of reaching repetitively through the transparent wall opposite to the opening. Data were collected
from HD andWTmonkeys (n = 4 per group). # indicates near significance (p = 0.07) and * indicates a p-
value < 0.05.
doi:10.1371/journal.pone.0122335.g001
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suppression with TE = 30 ms, TR = 1500 ms, and voxel size = 5 × 5 × 5 mm3. The cubic voxel
was placed in the right striatum and illustrated on 3 orthogonal structural images.
Volume calculation for whole brain and cortical structures. In order to calculate the
total brain volume (TBV), the skulls were stripped from all images using the FSL Brain Extrac-
tion Tool (BET) [41]. Skull-stripped brain images were then used to calculate the TBV. Each
structure (caudate nucleus and putamen) was manually outlined on coronal T1-weighted im-
ages using a monkey brain atlas [42]). The volume of each structure was then calculated with
ImageJ 1.47v (NIH). The striatal volume is the summation of caudate nucleus and putamen.
Magnetic resonance spectroscopic (MRS) analysis of NAA in the striatum. Concentra-
tions of cerebral metabolites, including N-acetylaspartate (NAA), creatine, and phosphocrea-
tine (Cr+PCr), were derived from the spectra of each animal at 48 months of age using the
LC-Model software [43]. Total creatine (Cr+PCr) levels were used as an internal reference for
the quantification of other metabolites [44,45]. The spectral results were analyzed and com-
pared statistically among the disease and control groups using Student’s t-test.
Statistical analysis of longitudinal MRI data. Linear mixed-effects models, carried out by
the “lme” function in R (www.r-project.org) version 2.15.1, were fitted to the longitudinal data
to account for the correlation of repeated measurements from the same subject. Specifically, we
used the model:
Yit ¼ b0 þ b1HDi þ b2timet þ b3  HDi  timet þ b4timet2 þ b5  HDi timet2
þ bi þ εit
where Yit is brain volume measurement at any ROI for the i
th subject at the tth time point,HDi
is 1 for HD monkeys and 0 for controls, timet is month of the t
th time point, bi is a random ef-
fect that follows N(0, sb2), and εit is an error term that follows N(0, σ
2) and is independent of
bi. To test for any difference in the trajectories between the HD and control monkeys, i.e., H0:
β1 = β3 = β5 = 0, we conducted the likelihood ratio test (LRT). P-values less than 0.05 were con-
sidered statistically signiﬁcant.
Reverse transcription and quantitative PCR (qPCR)
Total RNA from the caudate nucleus and putamen was isolated using Trizol and subsequently
treated with DNase to remove residual genomic DNA contamination. 500 ng DNA-free total
RNA was reverse transcribed in a total volume of 20 μL using MultiScribe Reverse Transcrip-
tase (Applied Biosystems) as outlined in the manufacturer’s protocol. Primers used for real-
time PCR were designed using Primer3Express and are listed below. Each qPCR reaction con-
sisted of 1X SsoAdvanced SYBR Green Supermix (Bio-Rad) with 0.4 μM each primer (S2
Table), and thermal cycling was performed according to the manufacturer’s protocol. All HTT
exon 1 data (primers amplified endogenous and transgenic HTT) were analyzed by normaliza-
tion to both ubiquitin C (Ubc; housekeeping gene) and/or HTT exon 26 (primers specifically
amplified endogenousHtt only).
Neuropathological analysis
Tissue preparation. Monkeys were deeply anesthetized with an overdose of pentobarbital
at the time of sacrifice. Brains were rapidly removed from the skull and post-fixed with 4%
paraformaldehyde, and then cryoprotected with 30% sucrose. The brains were frozen-sec-
tioned into serial 50-μm thick coronal sections and preserved at -80°C.
NeuN and mEM48 staining. Sections from one control, rHD1, and rHD7 monkeys were
immunostained with a specific primary antibody for neuronal nuclei (NeuN) and mHTT with
expanded polyQ (mEM48). Sections were then stained with associated secondary antibody and
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localized with avidin-biotin-peroxidase complex (ABC, VECTASTAIN ABC kit). Diamino-
benzidine (DAB) was used for the peroxidase reaction to reveal the staining.
Stereological cell counting. One in 12 sections of control and HDmonkeys were Nissl-
stained with cresyl violet. These sections were used for unbiased stereological cell counting
(Stereo Investigator, MBF BIOSCIENCE). The optical fractionator probe was used for counting
cell numbers. A region of interest (ROI) of striatum was delineated using a 2.5X objective, and
the sections were then examined with a 100X objective. Cells were counted at 100X from 65 x
65 μm unbiased counting frames within a randomly chosen 1200 x 1200 μm square grid. An
optical dissector height of 27 μm and a top guard zone height of 3 μm were used. The total
number of cells in the ROI was estimated with the section sampling fraction, the area sampling
fraction, and the mean section thickness [46].
Results
Cognitive and motor assessment of HDmonkeys
At 8 and 16 months of age, animals performed the object retrieval detour task (ORDT; Barrier/
Detour; S1 Table). Performance at 8 months of age was similar between rHDs6-8 andWT
monkeys (Fig 1a–1d; top panel), although the former displayed a slightly higher number of per-
severations in the difficult trials (Fig 1d) [t = 3.315 with 5 d.f., p = 0.021] (rHD1 was not as-
sessed at 8 months of age). Notably, testing conducted on HDmonkeys at 16 months of age
revealed a gradual impairment in motor function (Fig 1e–1h; bottom panel). They took longer
to retrieve the rewards than controls in both the easy (Trials 2–4) and difficult trials (Trials
5–7), although this group difference showed only a trend towards significance for the difficult
trials [t(5) = 2.34, p = 0.06] (Fig 1e); rHDs6-8 also performed more barrier reaches [t(5) = 2.60,
p = 0.048] (Fig 1f) and tended to have more perseverative errors [t(5) = 2.21, p = 0.07] (Fig 1h)
in the easy trials. They displayed significantly greater motor problems when attempting to re-
trieve the food rewards in all trials [U = 0.5, p = 0.04 and U = 0, p = 0.026, for easy and difficult
trials, respectively; Fig 1g]. Of note, although difficulties gradually emerged in rHDs6-8 as they
matured, rHD1 showed no impairment in the task at 16 months of age.
Visuomotor performance was assessed further at both 16 and 36 months of age using the vi-
suospatial orientation (VS-OR; Life Saver) task. At 16 months of age, there were no significant
differences between the HD andWT monkeys in any of the parameters tested (latency, fastest
times, and failures; Fig 2, left panel). At 36 months of age, however, rHDs6-8 required more
time to perform the task when more difficult patterns were used [t(5) = 3.73, p = 0.014, for la-
tency; Fig 2, right panel]. Note that testing of rHD1 in the Life Saver task was discontinued due
to the development of self-injurious behavior during the time this test was being administered.
Volumetric changes in the striatum of HDmonkeys
We performed 4 years of semiannual longitudinal measurements of volumetric changes in the
caudate nucleus and putamen using brain MRI data and normalized to the total brain volume
(TBV) for each individual in order to minimize inter-subject variations (Fig 3). Unlike rHD1,
which diverged distinctly fromWT at 24 months of age (Fig 3d and 3e), the volumetric reduc-
tion of both the caudate nucleus and putamen of rHDs6-8 was not significantly different from
control at each time point (Fig 3d and 3e). There was progressive enlargement of the ventricles
of rHD1 as the disease progressed, further confirming the occurrence of regional atrophy in
the area of the striatum (S2 and S3 Figs). Although no statistically significant striatal volumetric
reduction was observed in rHDs6-8 at specific ages (Fig 3d and 3e) when compared with WT
monkeys, we did see significantly different brain volume expansion trajectories (p< 0.05) as
determined by the likelihood ratio test (LRT). The overall trajectory of volumetric changes in
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rHDs6-8 over the period of this study indicated a decreasing inclination, which was significant-
ly different from the WTmonkeys. The brain volumes of rHDs6-8 stopped increasing by 24
(rHD7) or 36 (rHD6, 8) months of age, whereas brain volumes in WT monkeys continued to
grow at a slow and steady rate until the end of the 4-year study as they approached adulthood
(Fig 3d and 3e).
Fig 3. Longitudinal changes of striatal (caudate/putamen) volumes in HDmonkeys. (a-c)
Representative T1-weighted images of a control monkey, rHD1, and rHD6 indicating the regions of interest of
the caudate nucleus and putamen. (d) Longitudinal changes in caudate nucleus. (e) Longitudinal changes in
putamen. Control ( ), rHD1 ( ), rHD6 ( ), rHD7 ( ), and rHD8 ( ). Arrows indicate enlarged ventricles.
doi:10.1371/journal.pone.0122335.g003
Fig 2. Visuospatial orientation (Life Saver) task at 16 and 36months of age. Life Saver task was
performed at 16 (left panel) and 36 (right panel) months of age. Latency (sec) and fastest times (sec) to free a
ring-shaped candy (“Life Saver”) by moving it along metal rods of increasing difficulty. Easy rods contained
1–3 bends, and difficult rods contained 4–5 bends. Please note that testing of rHD1 in the Life Saver task had
to be discontinued due to the development of self-injurious behavior during testing. * indicates a significant
difference between HD andWTmonkeys (p < 0.05).
doi:10.1371/journal.pone.0122335.g002
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In parallel with the brain volume measurement using neuroimaging data, we measured
head size and body weight every 6 months to determine whether HD monkeys had different
growth trajectories (S4 Fig). After adjusting for gender, both the head size and body weight of
HD monkeys demonstrated significantly different trajectories compared with WTmonkeys
(p< 0.0002 and p< 0.0001, respectively). To further confirm that differences in brain volume
were not due to head size or body weight, brain volume was adjusted for head circumference,
body weight, and gender by including these parameters as covariates in the statistical analyses.
The trajectories of brain volume in different regions between HD and WTmonkeys remained
significantly different, with high significance (p< 0.0001).
Assessment of mHTT transgene expression, formation of HTT
aggregates, and neural cell loss in caudate nucleus and putamen
Although we saw progressive cognitive and motor impairment in rHDs6-8, volumetric mea-
surement of the caudate nucleus and putamen by MRI suggests no significant changes at each
time point, even though significant declining trajectories were seen in the rHDs. To determine
whether there was loss or damage to neuronal tissues in the striatum of HDmonkeys, in vivo
proton magnetic resonance spectroscopy (1H MRS) was used to measure striatal changes of
NAA, a surrogate marker of neuronal integrity, in the striatum (Fig 4a–4d). A decrease of
NAA has been used as an indicator for metabolic disturbances and neuronal loss in HD
[14,15]. MRS data showed a significantly lower level of NAA in the striatum of HD monkeys at
48 months of age when compared to the control monkeys (Fig 4e). The reduction of the NAA
level suggests neuronal damage or loss and was consistent with neural cell loss seen in the cau-
date nucleus and putamen of rHD1 and rHD7 (Figs 4 and 5). To further examine whether
Fig 4. Measurement of NAA levels in the striatum of HDmonkeys at 48 months of age by proton
magnetic resonance spectroscopy (1H MRS). 1H MRS obtained from (a) Control, (b) rHD1, (c) rHD7,
showing peaks of creatine (Cr) and N-acetylaspartate (NAA). (d) Location of the voxel used for 1H MRS in the
striatal region (white squares). (e) Comparison of NAA level between control (n = 4) and HDmonkeys (n = 4).
*p < 0.05.
doi:10.1371/journal.pone.0122335.g004
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striatal pathological changes could have contributed to the cognitive and motor deficits seen in
these animals, a quantitative neuropathological analysis was performed on the brains of 2 HD
monkeys (rHD1 and rHD7) when they were 5 years old. The expression levels ofmHTT tran-
script in the caudate nucleus and putamen were measured by qPCR (Fig 6a). As expected,
rHD1 had the highest HTT transcript levels compared to rHD7 and control, while the control
monkey had the lowest (Fig 6a). The expression levels ofmHTT were consistent with the extent
of HTT aggregates and intranuclear inclusions as shown by immunostaining on brain sections
using mEM48 antibody that specifically recognized mHTT with expanded polyglutamine re-
peats (Fig 6b–6e)[4]. rHD1 displayed more positively stained cells with intranuclear inclusions
(Fig 6b and 6c) compared with rHD7, whose positively stained cells were seen sparsely
throughout the sections (Fig 6d and 6e).
There was a significant volume reduction of the caudate nucleus and putamen in rHD1 (Fig
5A and 5C), which was consistent with the MRI study (Fig 3; S2 and S3 Figs). Unlike rHD1,
rHD7 displayed no obvious reduction in striatal volume or enlargement of ventricles compared
to the control at specific time points (Fig 5a and 5b); however, the total cell count by stereologi-
cal analysis of the caudate nucleus and putamen of rHD1 and rHD7 revealed a significantly
Fig 5. Reduced striatal neurons in the caudate nucleus and putamen of HDmonkeys. Immunostaining
with the neuronal-specific marker NeuN in the striatum in 5-year-old control (a), rHD7 (b), and rHD1 (c)
monkeys (scale bar = 1mm). The close-up view at the right side shows a closer view of the caudate nucleus
and putamen (scale bar = 100μm). The number of NeuN-positive neurons in the caudate nucleus (a’, b’, c’)
and putamen (a”, b”, c”) of the HDmonkeys is dramatically reduced compared with the control animal (scale
bar = 10 μm). By counting from the Nissl staining, the number of neurons in the caudate nucleus and
putamen is reduced in both HDmonkeys when compared to control monkeys (d, e, respectively).
doi:10.1371/journal.pone.0122335.g005
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lower number (caudate/putamen: Control-15000/22500; rHD7-11000/12500; rHD1-2500/
5000) of Nissl-positive (Fig 5d and 5e) and NeuN-positive cells (Fig 5b’ and 5c’; Fig 5b” and
5c”) when compared to the age-matched control monkey (Fig 5a’ and 5a”). Comparing rHD1
and rHD7, the striatum of rHD1 contained a much lower number of Nissl-positive cells (Fig
5d and 5e).
Discussion
This report focused on the longitudinal development of a spectrum of clinically and neuro-
pathologically relevant features in HDmonkeys from infancy to adulthood; their symptoms in-
cluded progressive cognitive and motor impairments, and neuropathological and chemical
changes of the striatum. To evaluate cognitive and motor performances, we used the ORDT to
assess the functional deficit of the fronto-striatal pathway, which is known to be one of the neu-
ral circuits affected in HD [16,17,18,19]. This task, which is commonly used in nonhuman pri-
mate models of HD [17,18,19] and Parkinson’s disease (PD) to assess changes in motor
planning skill, is sensitive for detecting frontal cortex and striatal dysfunction [16,17,18,19,20].
To further assess motor control as well as motor skill learning and reaction time, the “Life
Saver” task was used to interrogate the integrity of the mid- and posterior-putamen functions.
The Life Saver test has been widely used in nonhuman primate models of HD [21] and PD to
assess motor functions and visuospatial orientation [21,22,23,24,25]. Together, the ORDT and
Life Saver tasks revealed that rHDs6-8 developed progressive motor dysfunction and a lack of
behavioral inhibitory control; both of these symptoms are associated with HD onset/progres-
sion in humans and suggest a functional decline of the fronto-striatal pathways in HDmonkeys
Fig 6. Expression of mHTT transgenes and formation of mHTT aggregates in the caudate nucleus and
putamen of HDmonkeys.Quantitative measurement of mHTT transcript levels in the caudate nucleus and
putamen by qPCR (a). Immunostaining with mEM48 that specifically recognized mHTT with expanded polyQ
repeats in the caudate nucleus and putamen of rHD1 (b and c) and rHD7 (d and e), respectively. Scale
bar = 50 μm. Arrows: mEM48-positive cells with intranuclear inclusions. Arrowhead: mEM48-positive cell
presented at higher magnification in the insert.
doi:10.1371/journal.pone.0122335.g006
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[16]. These findings are consistent with the decreased brain volume in the striatum measured
from neuroanatomical imaging and neuronal loss found in neuropathology, and MRS analyses.
It is interesting to note that HD monkeys carrying 2 different transgenes (rHD1 vs rHDs6-8)
displayed different patterns of cognitive and motor impairment as well as neuroanatomical
changes (Figs 1–3, 5, 6 and S1 Fig).
The distinct pattern of transgene expression (Fig 6a), HTT aggregates and intranuclear in-
clusions (Fig 6b–6e), changes in striatal volume (Fig 3), neural cell loss (Fig 5), and reduced lev-
els of NAA (Fig 4) in rHD1 and rHD7 further point to differences between HDmonkeys that
carry different transgenes. rHD1 developed dystonia at least 6–8 months earlier than the other
rHDs and was also the only HD monkey to develop seizures at around 24 months of age (S1
Fig). An aggressive striatal atrophy in rHD1 began at 24 months of age, with approximately
47% and 30% volume reduction in the caudate nucleus and putamen at 48 months of age, re-
spectively (Fig 3). In contrast, the other 3 HD monkeys exhibited a relatively slower reduction
rate and blunted growth of the striatum at 24 and 36 months of age, while WT monkeys con-
tinued to grow throughout the period of this study (Fig 3). Although we saw significant declin-
ing trajectories in each of rHDs6-8, there was no significant reduction of the caudate nucleus
and putamen volume at any specific age based on longitudinal neuroimaging study (Fig 3),
which was further confirmed by the neuropathological examination of rHD7 brain (Fig 5). In-
terestingly, although we saw no obvious striatal atrophy in rHD7 when compared to control
and rHD1, who displayed enlarged lateral ventricles and significant striatal volume reduction
(Fig 6a–6c), we found a significant loss (~30–50%) in Nissl- and NeuN-positive cells in the cau-
date nucleus and putamen of rHD7 (Fig 5). Although only one control and two HDmonkeys
were used for the neuropathological study, the extent of regional atrophy in rHD1 and the dif-
ferences in the number of Nissl- and NeuN-positive cells between the control and HDmonkeys
are clear (Fig 5). While there was no obvious atrophy in rHD7 based on both MRI and neuro-
pathology, the significant cell loss in both caudate nucleus and putamen suggests a progressive
regional degeneration, which was further supported by the decrease of NAA at 48 months as
measured by 1HMRS (Fig 4). A similar change in NAA was seen in rHD6 and rHD8, suggest-
ing the presence of possible striatal neurodegeneration even though there was no noticeably
significant reduction of caudate nucleus or putamen volume (Figs 3 and 5). The loss of neural
cells in the striatum of rHD1 and rHD7 is consistent with our findings of cognitive and motor
impairment in these animals, possibly due to dysfunction in the fronto-striatal pathways and
abnormal striatal outflow (Figs 1 and 2). Based on our assessments, rHD1 presented with more
acute development of symptoms similar to juvenile HD, specifically with several episodes of
seizures, more aggressive development of dystonia at a young age and on throughout adult-
hood, and significant atrophy of the caudate nucleus and putamen [26,27,28,29]. On the other
hand, symptoms in rHDs6-8 were relatively mild, sporadic, and progressed at a much slower
rate and in a less aggressive manner compared to rHD1. These different behavioral outcomes
were expected based on the different genotypes of these animals, with rHDs6-8 mimicking
more closely the slow progression of the adult form of HD.
There are ongoing clinical longitudinal studies of HD patients, including TRACK-HD and
PREDICT-HD [9,30]. HD monkeys can be assessed based on human longitudinal trial results
and offer expanded assessment and therapeutic development opportunities that directly com-
plement the human subject work. Our parallel study using a large nonhuman primate animal
model that closely displays the progressive clinical features of HD offers a unique platform for
preclinical assessment of new treatments using cognitive behavioral tests of functions and neu-
roimaging methods for measuring neuroanatomical ad chemical changes. Moreover, rhesus
macaques share a motor repertoire similar to humans, allowing the evaluation of fine move-
ment control, which is impossible with most of the currently available model systems [31].
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Most importantly, we can evaluate the neurobehavioral impact of disease and treatment with a
sophisticated battery of cognitive and behavioral tests developed for macaques, which is often a
challenge in other species [21,32,33].
Since there is no perfect animal model for human diseases, an animal model that can repli-
cate human disease genetically and clinically is important to study specific pathogenic mecha-
nisms underlying inherited neurological disorders like HD that progresses as individuals age
[31,34]. A higher primate model such as rhesus macaque can play an important role in model-
ing diseases like HD because various biological systems, including those that regulate cognitive,
motor, and psychiatric functions [2,3,4,9,21,30], as well as metabolism [35,36,37], are progres-
sively impacted throughout the course of the disease. Because of its progressive nature, large
animal models, such as HD monkeys, could more effectively mimic the progression of HD-like
symptoms through longitudinal analysis with clinical measurements similar to those per-
formed in HD patients [3,5]. A direct comparison and alignment of disease symptom progres-
sion with the human condition based on clinical features is a challenging task because of the
fundamental differences between species. Our goal is to establish a progression timeline for dis-
ease development in HD monkeys by integrating information generated from different clinical
assessments (S1 Fig). Although this timeline may not align perfectly with humans with HD,
and there will be questions as to how well HD monkeys represent humans, we believe our
long-term longitudinal studies in HDmonkeys thus far represent one of the most extensive
and comprehensive animal studies. This nonhuman primate model encompasses progressive
development of HD from infancy to adulthood based on clinical assessment methods similar
to those used in humans. However, we acknowledge that our sample size in this study is limited
and that additional HD monkeys are needed to further confirm our findings and for the future
development of the HD monkey model. Nonetheless, longitudinal assessments on other cogni-
tive functions are ongoing and are expected to further support the initial results of the current
study that HDmonkeys could develop symptoms similar to those of human HD patients.
Conclusions
We present the findings of progressive decline in cognitive and motor functions and related
neuroanatomical and chemical changes in HDmonkeys based on longitudinal assessments
from infancy to adulthood. The neuropathology in two of the HD monkeys further demon-
strated a progressive degenerating process in the striatum of HD monkeys and indicated that
extensive cell loss precedes significant loss of brain mass in striatum. Comparison of HD mon-
keys also suggests that different N-terminal HTT fragments cause distinct neuropathology.
This study demonstrates the potential of transgenic HDmonkeys to model human HD in facil-
itating preclinical research and advancing biomedical research in the quest for a cure for HD.
Supporting Information
S1 Fig. Timeline of progressive development of clinical features in HDmonkeys. Specific
types of impairment, including cognitive motor functions and neuroanatomical changes, are
plotted on a timeline for rHDs6-8 (top) and rHD1 (bottom).
(TIF)
S2 Fig. Coronal T1-weighted images of WT control monkey and rHD1 at 12, 24, 36, and 48
months of age.
(TIF)
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S3 Fig. Volumetric changes in HD brain observed in T1-weighted images of rHD1 and a
control monkey at four years of age. Arrows indicate enlarged ventricle.
(TIF)
S4 Fig. Head circumference and body weight of HDmonkeys. Controls 1 and 2 are female
monkeys. Controls 3 and 4 are male monkeys.
(TIF)
S1 Table. Definitions of behavioral measures in the ORDT.
(DOCX)
S2 Table. List of primers.
(DOCX)
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